Compare Oxford Lane Capital Corp (OXLC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Zoetis Inc — how do they compare? Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 36.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 50 Days and Zoetis Inc for 70 Days on average.
| OXLC | ZTS | |
|---|---|---|
Market Cap | $835.71M | $30.20B |
Volume | 1,125,263 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $16.74 | $147.53 |
52-Week Low | $8.15 | $69.09 |
Typical Hold Time | 50 Days | 70 Days |
Enterprise Value | $1.23B | $37.76B |
Dividend Yield | 28.15% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.53, up 0.83% today, but faces significant fundamental challenges with a negative ROE of -39.16% and recent earnings misses. Technical indicators show a bearish trend with strong selling pressure on moving averages, though RSI suggests potential oversold conditions. The company maintains a consistent $0.20 monthly dividend while navigating substantial net asset value declines reported in recent updates.
The outlook remains cautious with deteriorating fundamentals offset by high dividend yield. Key risks include unsustainable payout ratios and NAV erosion, while potential upside exists if CLO market conditions stabilize. Analyst sentiment is divided with 50% buy ratings but technicals indicate continued downward pressure.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
